Korean J Clin Oncol.  2016 Jun;12(1):41-47. 10.14216/kjco.16007.

Oncologic outcomes of squamous cell carcinoma of the anal canal after chemoradiation therapy

• Lim DR
• Hur H
• Min BS
• Baik SH
• Lee KY
• Kim NK

• KMID: 2360702
• DOI: http://doi.org/10.14216/kjco.16007

Abstract

PURPOSE
The aim of this study is to analyze the oncological outcomes of squamous cell carcinoma (SCC) of the anal canal after chemoradiation therapy (CRT) in a single institution.
METHODS
Fifty-one patients with anal SCC who had been treated with CRT between January 2000 and December 2010 were analyze data single center in Korea.
RESULTS
Forty-eight patients exhibited clinical complete response. After a median follow-up of 42.1 months, 13 patients (25.5%) showed recurrence. The disease-free survival (DFS) rate was 63.4% at 5 and 10 years. The overall survival (OS) rates were 83.6% (5 years) and 75.2% (10 years). Stage I: DFS, 100%; OS, 100%; stage II: DFS, 85.7%; OS, 100%; stage IIIA: DFS, 68.6%; OS, 87.5%; stage IIIB: DFS, 34.7%; OS, 48.4%; and stage IV: DFS and OS, 0%. The local recurrence patterns were as follows: pelvic node (n=4, 7.8%), inguinal node (n=1, 2.0%), and inguinal and pelvic node (n=1, 2.0%). The systemic recurrence patterns were as follows: lung (n=2, 3.9%), para-aortic node (n=1, 2.0%), and extrapelvic site (n=2, 3.9%). N-stage represented a single independent prognostic factor for recurrence (P<0.05).
CONCLUSION
CRT for SCC of the anal canal is effective for oncological outcomes and sphincter preservation. The initial nodal status may affect the oncological outcome.

Keyword

Squamous cell carcinoma; Anal neoplasms; Chemoradiotherapy

MeSH Terms

Anal Canal*
Anus Neoplasms
Carcinoma, Squamous Cell*
Chemoradiotherapy
Disease-Free Survival
Epithelial Cells*
Follow-Up Studies
Humans
Korea
Lung
Recurrence